Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049159 · ClinicalTrials.gov registry record · Phase 2
Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old
A Phase 2 study of Shigella, sponsored by Eveliqure Biotechnologies.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT07049159: Recruiting Phase 2 study of Shigella, sponsored by Eveliqure Biotechnologies.
NCT07049159 is a Phase 2 study of Shigella that is actively recruiting participants, run by Eveliqure Biotechnologies. The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07049159, a Phase 2 study of Shigella, is actively recruiting participants, sponsored by Eveliqure Biotechnologies.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of the oral, live, attenuated ShigETEC vaccine against challenge with S. flexneri 2457T. In Stage 1 of this study, ShigETEC vaccine or placebo will be administered orally to healthy participants at a dose of 5x10\^10 CFU. This dose was tested in a Phase 1 trial and found to be safe when given 4 times with an interval of 3 days between each dose. The efficacy of ShigETEC vaccination will be evaluated in Stage 2 of this study, when participants will be challenged with S. flexneri 2457T. The study population will be healthy adult participants in the age of 18-50 years (inclusive), which are clearly defined in the study protocol.
Primary Outcome
The proportion of participants with incidence of shigellosis caused by the challenge strain in vaccine vs. placebo recipients until the start of antibiotic administration.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL ShigETEC vaccine
- BIOLOGICAL Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU
Study Locations (1)
Maryland
- Center for Immunization Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2027-05-23 |
| Phase | Phase 2 |
What NCT07049159 shows while recruiting
NCT07049159 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Shigella appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07049159 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07049159 about?
NCT07049159 is a clinical study titled "Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old". The purpose of this study is to evaluate the efficacy of the oral, live, attenuated ShigETEC vaccine against challenge with S. flexneri 2457T. In Stage 1 of this study, ShigETEC vaccine or placebo will be administered orally to healthy participants at a dose of 5x10\^10 CFU. This dose was tested in...
What is the current status of trial NCT07049159?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2025-06-30. Estimated completion is 2027-05-23.
What conditions does trial NCT07049159 study?
This clinical trial studies the following conditions: Shigella.
What interventions are being tested in trial NCT07049159?
The interventions under investigation include: Placebo (OTHER), ShigETEC vaccine (BIOLOGICAL), Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU (BIOLOGICAL).
Who is sponsoring clinical trial NCT07049159?
This trial is sponsored by Eveliqure Biotechnologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07049159 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shigella
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07049159's enrollment target sits among peer trials
72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI